However, in the MARIANNE trial, T-DM1 failed to show a survival advantage of T-DM1 and pertuzumab in comparison to trastuzumab plus taxane chemotherapy in the first-line setting for metastatic HER2+ breast cancer [9]. This evidence concerns the gene ERBB2 and breast carcinoma.